17-Apr-2026
Globe Newswire (Fri, 20-Mar 4:30 PM ET)
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
Globe Newswire (Mon, 16-Mar 7:30 AM ET)
Zevra’s 2025 Financials Signal Turnaround as MIPLYFFA Drives Rare Disease Momentum
Market Chameleon (Tue, 10-Mar 5:53 AM ET)
Business Wire (Tue, 10-Mar 8:30 AM ET)
Market Chameleon (Tue, 10-Mar 3:06 AM ET)
Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
Globe Newswire (Mon, 9-Mar 4:05 PM ET)
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer
Globe Newswire (Thu, 5-Mar 7:30 AM ET)
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
Globe Newswire (Mon, 2-Mar 7:30 AM ET)
Zevra Therapeutics to Present at the Citizens Life Sciences Conference
Globe Newswire (Wed, 25-Feb 7:30 AM ET)
Globe Newswire (Tue, 24-Feb 3:42 PM ET)
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Zevra Therapeutics trades on the NASDAQ stock market under the symbol ZVRA.
As of April 17, 2026, ZVRA stock price climbed to $10.67 with 1,135,269 million shares trading.
ZVRA has a beta of 0.53, meaning it tends to be less sensitive to market movements. ZVRA has a correlation of 0.02 to the broad based SPY ETF.
ZVRA has a market cap of $626.45 million. This is considered a Small Cap stock.
Last quarter Zevra Therapeutics reported $34 million in Revenue and $.19 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.14.
In the last 3 years, ZVRA traded as high as $13.16 and as low as $3.89.
The top ETF exchange traded funds that ZVRA belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
ZVRA has outperformed the market in the last year with a price return of +49.2% while the SPY ETF gained +36.3%. ZVRA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +19.5% and +13.5%, respectively, while the SPY returned +2.9% and +8.3%, respectively.
ZVRA support price is $10.09 and resistance is $10.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZVRA shares will trade within this expected range on the day.
